2019
Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation
Correa DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE, DeAngelis LM, Omuro A. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. Journal Of Neuro-Oncology 2019, 144: 553-562. PMID: 31377920, PMCID: PMC7392129, DOI: 10.1007/s11060-019-03257-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCognitionCombined Modality TherapyCranial IrradiationFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansInduction ChemotherapyLongitudinal StudiesLymphomaMaleMiddle AgedPrognosisQuality of LifeSurvival RateTransplantation, AutologousYoung AdultConceptsWhole brain radiotherapyReduced-dose whole-brain radiotherapyPrimary central nervous system lymphomaHDC-ASCTCortical atrophyAttention/executive functionPCNSL patientsAutologous stem cell transplantConsolidation whole-brain radiotherapyAutologous stem cell transplantationCentral nervous system lymphomaCognitive functionIntroductionThe standard treatmentLongitudinal cognitive assessmentsProgression-free patientsHigh-dose chemotherapyMethotrexate-based chemotherapyLong-term remissionPrimary CNS lymphomaNervous system lymphomaStem cell transplantStem cell transplantationBrain structure abnormalitiesPost-induction chemotherapyWhite matter disease
2015
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial
Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio M, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy M, Hoang-Xuan K. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. The Lancet Haematology 2015, 2: e251-e259. PMID: 26688235, DOI: 10.1016/s2352-3026(15)00074-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCytarabineDacarbazineDisease-Free SurvivalFemaleHumansLymphomaMaleMethotrexateMiddle AgedProcarbazineProspective StudiesQuality of LifeTemozolomideTreatment OutcomeVincristineConceptsPrimary CNS lymphomaProgression-free survivalKarnofsky Performance Scale scoreCytarabine groupPhase 2 trialCNS lymphomaPerformance Scale scoreTemozolomide groupElderly populationScale scoreMedian progression-free survivalPhase 2 trial designCommon grade 3Methotrexate-based regimensProphylactic G-CSFMedian overall survivalStandard chemotherapy regimenPoor prognosis patientsQuality of lifeChemotherapy regimenEfficacy endpointPrimary endpointPrognosis patientsElderly patientsImmunocompetent patients
2013
Bevacizumab for acute neurologic deterioration in patients with glioblastoma
Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncology 2013, 2: 413-418. PMID: 25054664, PMCID: PMC6136096, DOI: 10.2217/cns.13.40.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabBrainBrain NeoplasmsGlioblastomaHumansInpatientsKarnofsky Performance StatusMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalQuality of LifeRetrospective StudiesSurvival AnalysisTreatment OutcomeYoung AdultConceptsNeurologic dysfunctionNeurologic deteriorationOutpatient treatmentGlioblastoma patientsAcute neurologic dysfunctionDose of bevacizumabAcute neurologic deteriorationSevere neurologic dysfunctionQuality of lifeBevacizumab treatmentHospitalized patientsRetrospective reviewSteroid dependenceDexamethasone administrationRehabilitation admissionTumor locationPeritumoral edemaBevacizumabPatientsAbstractTextDysfunctionTreatmentGlioblastomaHospitalizationEdema
2011
Cognitive functions in primary CNS lymphoma after single or combined modality regimens
Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, Thaler HT. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-Oncology 2011, 14: 101-108. PMID: 22013168, PMCID: PMC3245999, DOI: 10.1093/neuonc/nor186.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyPrimary CNS lymphomaQuality of lifeHD-MTXWhite matter diseaseModality regimenCNS lymphomaHigh-dose methotrexate-based chemotherapyCognitive impairmentExtensive white matter diseaseMethotrexate-based chemotherapySubset of patientsBaseline neuropsychological evaluationBrain radiotherapyDisease remissionModality regimensMost cognitive domainsStandard treatmentTreatment completionCognitive dysfunctionSufficient severityPatientsNeuropsychological evaluationCognitive functionSubstantial risk